Josep Llovet

Josep Llovet is a leading liver cancer researcher who co-developed the BCLC staging system and was senior author of the SHARP trial establishing sorafenib as the first effective systemic therapy for advanced HCC. His laboratory characterizes the molecular heterogeneity of HCC and identifies therapeutic targets through genomic and functional studies. He has led multiple clinical trials of molecularly targeted agents and immunotherapy in HCC. He is among the most highly cited liver cancer researchers worldwide and directs major HCC research programs at both Mount Sinai and Barcelona.